Pharmaids Pharmaceuticals has announced the scheduling of its 37th Annual General Meeting (AGM) for Friday, September 11, 2026. The meeting will commence at 12:00 noon and will be conducted exclusively through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs circulars and SEBI Listing Regulations.

The company has dispensed with the requirement of sending physical copies of the AGM notice and annual report, adhering to recent regulatory dispensations. Shareholders whose email addresses are registered with their Depository Participants or the Registrar and Transfer Agent will receive the notice electronically. Those without registered emails will receive a letter containing a web link to access the documents on the company’s website.

E-Voting Schedule

Shareholders holding shares as of the cut-off date may exercise their voting rights using the electronic voting facility provided by Central Depository Services (India) Limited (CDSL). The remote e-voting window opens three days before the meeting and closes two days prior.

Members who cast their votes during the remote e-voting period may attend the AGM via VC/OAVM but are not entitled to vote again. Voting rights are proportionate to the paid-up equity share capital held as of the cut-off date.

Shareholder Instructions

To participate in the AGM or cast votes, shareholders must ensure their contact details are updated. Demat holders are advised to register their email addresses and bank details with their respective Depository Participants. Physical shareholders must submit KYC details via Form ISR-1 to the Registrar and Transfer Agent, Venture Capital and Corporate Investments Private Limited.

Queries regarding the e-voting system can be directed to CDSL at helpdesk.evoting@cdslindia.com or via toll-free numbers. The company secretary, Prasanna Subramanya Bhat, signed the disclosure under Regulation 30 of SEBI Listing Regulations, confirming the publication of this information in national newspapers.

Pharmaids Pharmaceuticals Limited has scheduled its 37th Annual General Meeting (AGM) for September 11, 2026, to approve its financial results for FY26. The company posted a significant increase in top-line growth alongside a widening bottom-line loss, driven by higher operational costs and finance expenses.

On a standalone basis, revenue from operations surged 353% to ₹106.0 crore from ₹23.4 crore in FY25. However, this growth was offset by a rise in total expenses to ₹283.3 crore from ₹119.5 crore, resulting in a net loss of ₹104.4 crore compared to ₹72.8 crore previously. Consolidated revenue rose 43% to ₹278.8 crore from ₹194.5 crore, while the consolidated net loss narrowed slightly to ₹115.7 crore from ₹135.1 crore.

Key Financial Metrics

Strategic Disinvestments and Related Party Transactions

During FY26, Pharmaids executed several material transactions to restructure its portfolio. The company disinvested its entire 66.50% partnership interest in Anugraha Chemicals for an overall value of ₹102.4 crore, comprising consideration for the stake and settlement of dues. Additionally, Adita Bio Sys Private Limited, a material subsidiary, ceased holding a step-down subsidiary, Siri Labvivo Diet Private Limited, following a share transfer to an unrelated party.

In a related party transaction, the company sold three land parcels in Tumkur to Dr. S. N. Vinaya Babu, then Chairman and now Vice-Chairman, for ₹19.4 crore. The transaction was approved by shareholders via postal ballot and determined on an arm’s-length basis. The Board also recommended no dividend for the year.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the operational weight of its subsidiaries. While the standalone entity saw revenue triple, it incurred a gross operating loss as expenses nearly tripled relative to the prior year. Conversely, the consolidated group showed more moderate revenue growth but managed to reduce the absolute net loss, suggesting that subsidiary operations, despite their own challenges, provided some stabilizing effect on the group's overall bottom line compared to the parent company's standalone trajectory.